Lilly Gets FDA Approval for Eczema Drug Ebglyss [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved for use in adults and children aged 12 and above who weigh at least 40 kgs and whose moderate-to-severe atopic dermatitis is not well controlled with topical prescription medicines. Ebglyss was approved in the European Union in 2023 and in Japan in January this year. The drug generated sales of $7.5 million in the first half of 2024. Year to date, Lilly's stock has risen 58.5% compared with the industry's 25.2% growth. The stock has also outperformed the sector as well as the S&P 500. LLY Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research More on LLY's Ebglyss Ebglyss' approval in the United States was based on data from ADvocate 1, ADvocate 2 and ADhere studies. Data from these studies showed that patients treated with Ebglyss experie
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Business Collaborative for Brain Health Partners with HERO to Launch the Brain Health Best Practice Score for Employers [Yahoo! Finance]Yahoo! Finance
- 1 Unstoppable Stock That Could Join the $1 Trillion Club in 2025 [Yahoo! Finance]Yahoo! Finance
- Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth [Yahoo! Finance]Yahoo! Finance
- Top Stock Picks for Week of September 16, 2024 [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock.MarketBeat
LLY
Earnings
- 8/8/24 - Beat
LLY
Sec Filings
- 9/18/24 - Form 3
- 9/17/24 - Form 4
- 9/17/24 - Form 4
- LLY's page on the SEC website